{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:40:55Z","timestamp":1792233655082,"version":"4.4.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":70,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["JCYJ20230807091503007"],"award-info":[{"award-number":["JCYJ20230807091503007"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471093"],"award-info":[{"award-number":["82471093"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA1108700"],"award-info":[{"award-number":["2024YFA1108700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clinthera.2026.07.007","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T19:26:41Z","timestamp":1786217201000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse Drug Events Associated With Six Classes of Glaucoma Medications: A Retrospective Pharmacovigilance Study Using Real-World Data From The FAERS Database"],"prefix":"10.1016","author":[{"given":"Yuqi","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuguo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.07.007_bib0001","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.11686","article-title":"Epidemiology of glaucoma: the past, present, and predictions for the future","author":"Allison","year":"2020","journal-title":"Cureus"},{"issue":"13","key":"10.1016\/j.clinthera.2026.07.007_bib0002","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1038\/s41433-023-02382-6","article-title":"Epidemiology and long-term outcomes of primary congenital glaucoma: a population-based study","volume":"37","author":"Nutt","year":"2023","journal-title":"Eye (Lond Engl)"},{"issue":"3","key":"10.1016\/j.clinthera.2026.07.007_bib0003","first-page":"253","article-title":"Glaucoma: diagnosis and management","volume":"107","author":"Michels","year":"2023","journal-title":"Am Fam Physician"},{"issue":"9","key":"10.1016\/j.clinthera.2026.07.007_bib0004","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ophtha.2023.05.001","article-title":"Association of systemic medication use with glaucoma and intraocular pressure: the European Eye Epidemiology Consortium","volume":"130","author":"Vergroesen","year":"2023","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.clinthera.2026.07.007_bib0005","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ophtha.2008.12.040","article-title":"Iris morphologic changes related to alpha(1)-adrenergic receptor antagonists implications for intraoperative floppy iris syndrome","volume":"116","author":"Prata","year":"2009","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.clinthera.2026.07.007_bib0006","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/13543776.2019.1665023","article-title":"Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013-2019)","volume":"29","author":"Nocentini","year":"2019","journal-title":"Expert Opin Ther Pat"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2026.07.007_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bjophthalmol-2025-egsguidelines","article-title":"European Glaucoma Society - terminology and guidelines for glaucoma, 6th Edition","volume":"109","author":"Pazos","year":"2025","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10.1016\/j.clinthera.2026.07.007_bib0008","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ophtha.2023.05.001","article-title":"Association of systemic medication use with glaucoma and intraocular pressure: the European Eye Epidemiology Consortium","volume":"130","author":"Vergroesen","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2025.07.009","article-title":"Efficacy and drug interactions of glaucoma medications: a systematic review and component network meta-analysis","author":"Hsia","year":"2025","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.clinthera.2026.07.007_bib0010","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1517\/13543784.6.8.1063","article-title":"Brimonidine","volume":"6","author":"Cantor","year":"1997","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"10.1016\/j.clinthera.2026.07.007_bib0011","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00002018-199308050-00004","article-title":"Systemic and local tolerability of ophthalmic drug formulations. An update","volume":"8","author":"Hugues","year":"1993","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/20420986241285929","article-title":"Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database","volume":"15","author":"Wu","year":"2024","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0013","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ajo.2023.03.014","article-title":"A systematic review and meta-analysis of systemic antihypertensive medications with intraocular pressure and glaucoma","volume":"255","author":"Leung","year":"2023","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.clinthera.2026.07.007_bib0014","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: the good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"10.1016\/j.clinthera.2026.07.007_bib0015","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: the good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2024.101261","article-title":"Addressing neurodegeneration in glaucoma: mechanisms, challenges, and treatments","volume":"100","author":"Bou Ghanem","year":"2024","journal-title":"Prog Retin Eye Res"},{"issue":"10","key":"10.1016\/j.clinthera.2026.07.007_bib0017","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/13543776.2019.1665023","article-title":"Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013-2019)","volume":"29","author":"Nocentini","year":"2019","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcjo.2026.03.017","article-title":"Systemic and ophthalmic drugs associated with glaucoma: an international, population-based observational study","author":"Lakhani","year":"2026","journal-title":"Can J Ophthalmol, J Can ophtalmol"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0019","article-title":"Ocular adverse reactions associated with intraocular pressure-reducing drugs: an analysis of the FDA adverse event reporting system (FAERS)","author":"Liu","year":"2026","journal-title":"Int J Risk Saf Med"},{"issue":"2","key":"10.1016\/j.clinthera.2026.07.007_bib0020","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol, Pract"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0021","doi-asserted-by":"crossref","DOI":"10.1177\/20420986241303428","article-title":"Adverse drug events associated with capecitabine: a real-world pharmacovigilance study based on the FAERS database","volume":"15","author":"Liu","year":"2024","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0022","doi-asserted-by":"crossref","DOI":"10.1177\/20420986241285929","article-title":"Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database","volume":"15","author":"Wu","year":"2024","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"10.1016\/j.clinthera.2026.07.007_bib0023","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/ceo.14454","article-title":"Drug-associated glaucoma: a real-world study based on the Food and Drug Administration adverse event reporting system database","volume":"53","author":"Wu","year":"2025","journal-title":"Clin Exp Ophthalmol"},{"issue":"9","key":"10.1016\/j.clinthera.2026.07.007_bib0024","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1167\/tvst.13.9.17","article-title":"Drug-related keratitis: a real-world FDA adverse event reporting system database study","volume":"13","author":"Wu","year":"2024","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41433-025-04035-2","article-title":"Drug-related retinal detachment pharmacovigilance signals in the real world: evidence from the FDA Adverse Event Reporting System","author":"Chen","year":"2025","journal-title":"Eye (Lond Engl)"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177820","article-title":"Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database","volume":"1002","author":"Wu","year":"2025","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.clinthera.2026.07.007_bib0027","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/s41598-024-84679-4","article-title":"Real world pharmacovigilance assessment of drug related macular degeneration risks","volume":"15","author":"Chen","year":"2025","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.clinthera.2026.07.007_bib0028","article-title":"Real-world large sample assessment of drug-related dry eye risk: based on the FDA adverse event reporting system database","volume":"13","author":"Wu","year":"2024","journal-title":"Asia-Pac J Ophthalmol (Phila Pa,)"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1349636","article-title":"Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data","volume":"15","author":"Ding","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0030","doi-asserted-by":"crossref","first-page":"8148","DOI":"10.1038\/s41598-025-92605-5","article-title":"Adverse events reporting of edaravone: a real-world analysis from FAERS database","volume":"15","author":"Shang","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.clinthera.2026.07.007_bib0031","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","article-title":"Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database","volume":"22","author":"Zhou","year":"2024","journal-title":"BMC med"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2025.119484","article-title":"Gastrointestinal adverse events associated with SNRIs: a FAERS-based pharmacovigilance study","volume":"387","author":"Lin","year":"2025","journal-title":"J Affect Disord"},{"issue":"10","key":"10.1016\/j.clinthera.2026.07.007_bib0033","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/apt.16601","article-title":"Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database","volume":"54","author":"Wichelmann","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.clinthera.2026.07.007_bib0034","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12916-024-03537-2","article-title":"Differences in hypersensitivity reactions and gadolinium deposition disease\/symptoms associated with gadolinium exposure to gadolinium-based contrast agents: new insights based on global databases VigiBase, FAERS, and IQVIA-MIDAS","volume":"22","author":"Qu","year":"2024","journal-title":"BMC med"},{"issue":"6","key":"10.1016\/j.clinthera.2026.07.007_bib0035","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jaad.2025.02.031","article-title":"Postmarketing safety surveillance of adalimumab, secukinumab, and infliximab in hidradenitis suppurativa: an analysis of the FDA adverse events reporting system (FAERS) database","volume":"92","author":"Joshi","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103385","article-title":"Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data","volume":"86","author":"Wang","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.clinthera.2026.07.007_bib0037","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jaad.2025.05.1417","article-title":"A disproportionality analysis of thromboembolic and cardiovascular adverse event signal strength across various JAK-inhibitors based on the FAERS database","volume":"93","author":"Zheng","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0038","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jad.2025.04.087","article-title":"Analysis of risk signals for viloxazine in the treatment of attention deficit hyperactivity disorder based on the FAERS database","volume":"382","author":"Wang","year":"2025","journal-title":"J Affect Disord"},{"issue":"6","key":"10.1016\/j.clinthera.2026.07.007_bib0039","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/pds.2247","article-title":"Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and multi-item gamma Poisson Shrinker","volume":"21","author":"Berlin","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.clinthera.2026.07.007_bib0040","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.mcna.2021.01.004","article-title":"Glaucoma","volume":"105","author":"Kang","year":"2021","journal-title":"Med clin N Am"},{"issue":"2","key":"10.1016\/j.clinthera.2026.07.007_bib0041","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2020.21899","article-title":"Glaucoma in adults-screening, diagnosis, and management: a review","volume":"325","author":"Stein","year":"2021","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.clinthera.2026.07.007_bib0042","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0043","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ajo.2022.05.007","article-title":"Adverse effects and safety in glaucoma patients: agreement on clinical trial outcomes for reports on eye drops (ASGARD)-A Delphi Consensus Statement","volume":"241","author":"Thein","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.clinthera.2026.07.007_bib0044","article-title":"Drug delivery systems in glaucoma - Current innovations and future perspectives","volume":"14","author":"Tan","year":"2025","journal-title":"Asia-Pac J Ophthalmol (Phila Pa,)"},{"issue":"4","key":"10.1016\/j.clinthera.2026.07.007_bib0045","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: the good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0046","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ajo.2022.05.007","article-title":"Adverse Effects and Safety in Glaucoma Patients: agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-a Delphi Consensus Statement","volume":"241","author":"Thein","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.clinthera.2026.07.007_bib0047","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.tips.2011.02.010","article-title":"Evolution of \u03b2-blockers: from anti-anginal drugs to ligand-directed signalling","volume":"32","author":"Baker","year":"2011","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"10.1016\/j.clinthera.2026.07.007_bib0048","first-page":"587","article-title":"Beta-adrenergic receptor blocker poisoning","volume":"43","author":"Reingardiene","year":"2007","journal-title":"Med (Kaunas Lith)"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0049","doi-asserted-by":"crossref","unstructured":"Abbas, SA, Hamadani, SM, Ahmad, U, et al. Ophthalmic timolol and hospitalization for symptomatic bradycardia and syncope: a case series. Cureus 12(3):e7270. doi:10.7759\/cureus.7270.","DOI":"10.7759\/cureus.7270"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.06.003","article-title":"Cholinergic nervous system and glaucoma: from basic science to clinical applications","volume":"72","author":"Faiq","year":"2019","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"10.1016\/j.clinthera.2026.07.007_bib0051","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamaophthalmol.2022.0059","article-title":"Safety and efficacy of AGN-190584 in individuals with presbyopia: The GEMINI 1 phase 3 randomized clinical trial","volume":"140","author":"Waring","year":"2022","journal-title":"JAMA Ophtha."},{"key":"10.1016\/j.clinthera.2026.07.007_bib0052","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2024.10.035","article-title":"Using real-world data to assess the association of retinal detachment with topical pilocarpine use","volume":"271","author":"Elhusseiny","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"17","key":"10.1016\/j.clinthera.2026.07.007_bib0053","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231710080","article-title":"A narrative review of the association between obstructive sleep apnea and glaucoma in adults","volume":"23","author":"Leggewie","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.clinthera.2026.07.007_bib0054","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/13543776.2019.1665023","article-title":"Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013-2019)","volume":"29","author":"Nocentini","year":"2019","journal-title":"Expert Opin Ther Pat"},{"issue":"12","key":"10.1016\/j.clinthera.2026.07.007_bib0055","article-title":"Allergic reactions to brimonidine 0.15%: a case series","volume":"17","author":"Mat Nawi","year":"2025","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.clinthera.2026.07.007_bib0056","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/jdv.17928","article-title":"Dermatological adverse effects of anti-glaucoma eye drops: a review","volume":"36","author":"Patchinsky","year":"2022","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"issue":"1","key":"10.1016\/j.clinthera.2026.07.007_bib0059","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0021-5155(99)00147-1","article-title":"Efficacy and safety of latanoprost eye drops for glaucoma treatment: a 1-year study in Japan","volume":"44","author":"Suzuki","year":"2000","journal-title":"Jpn J Ophthalmol"},{"issue":"6441","key":"10.1016\/j.clinthera.2026.07.007_bib0060","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/bmj.289.6441.347","article-title":"Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function","volume":"289","author":"Cowan","year":"1984","journal-title":"Br Med J (Clin Res Ed,)"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.117111","article-title":"Exploration of 1,2,3-triazole linked benzenesulfonamide derivatives as isoform selective inhibitors of human carbonic anhydrase","volume":"77","author":"Kakakhan","year":"2023","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.124232","article-title":"Discovery of novel benzenesulfonamides incorporating 1,2,3-triazole scaffold as carbonic anhydrase I, II, IX, and XII inhibitors","volume":"239","author":"Buza","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0063","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3389\/fphar.2019.00679","article-title":"Efficacy and safety of brinzolamide as add-on to prostaglandin analogues or \u03b2-blocker for glaucoma and ocular hypertension: a systematic review and meta-analysis","volume":"10","author":"Liu","year":"2019","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.clinthera.2026.07.007_bib0064","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2165\/00003495-199141040-00002","article-title":"New developments in the drug treatment of glaucoma","volume":"41","author":"Hurvitz","year":"1991","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.clinthera.2026.07.007_bib0065","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/archopht.124.9.1230","article-title":"Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial","volume":"124","author":"Sherwood","year":"2006","journal-title":"Arch Ophthalmol"},{"issue":"7432","key":"10.1016\/j.clinthera.2026.07.007_bib0066","first-page":"156","article-title":"Glaucoma\u20132: treatment","volume":"328","author":"Khaw","year":"2004","journal-title":"BMJ (Clin Res ed,)"},{"key":"10.1016\/j.clinthera.2026.07.007_bib0067","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ajo.2022.05.007","article-title":"Adverse Effects and Safety in Glaucoma Patients: agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement","volume":"241","author":"Thein","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.clinthera.2026.07.007_bib0068","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: the good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"10.1016\/j.clinthera.2026.07.007_bib0069","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/bjo.86.4.418","article-title":"Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication","volume":"86","author":"Pisella","year":"2002","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.clinthera.2026.07.007_bib0070","doi-asserted-by":"crossref","first-page":"180","DOI":"10.5694\/mja2.50020","article-title":"Current management of glaucoma","volume":"210","author":"Lusthaus","year":"2019","journal-title":"Med J Aust"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826002687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826002687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T09:44:25Z","timestamp":1792230265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826002687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":68,"alternative-id":["S0149291826002687"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.07.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse Drug Events Associated With Six Classes of Glaucoma Medications: A Retrospective Pharmacovigilance Study Using Real-World Data From The FAERS Database","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}